Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Second J & J Plant Under Federal Investigation

By Drug Discovery Trends Editor | July 20, 2010

TRENTON, N.J. (AP) – A second Johnson & Johnson medicine factory is under scrutiny from federal regulators, while the company struggles to deal with bad publicity and repeated recalls at another factory.

The healthcare giant in April shut down a plant in Fort Washington, a Philadelphia suburb, that’s now linked to eight recalls of Tylenol and other nonprescription drugs for children and adults.

Now the Food and Drug Administration has sent the company a critical report after a recent inspection found problems at another Pennsylvania plant, in Lancaster.

New Brunswick, N.J.-based J&J said Monday that it’s addressing the FDA’s concerns as quickly as possible.

The news comes just before Johnson & Johnson is to release its second-quarter earnings results Tuesday morning, followed by a conference call with analysts who are sure to grill company executives about the repeated problems.

An FDA official two months ago told Congress the agency had broadened its investigation beyond the Fort Washington plant and also had turned the case over to its Office of Criminal Investigations.

The Lancaster plant is operated by a joint venture called Johnson & Johnson/Merck Consumer Pharmaceuticals Co. The business sells products, including heartburn medicine Pepcid, that originally were sold as prescription drugs and now are available in over-the-counter, lower-dose versions. Merck & Co. of Whitehouse Station, N.J., is J&J’s partner in the operation.

FDA spokeswoman Elaine Gansz Bobo said the report is still under review and cannot be released publicly until sensitive commercial information has been blacked out. That’s the agency’s standard practice.

She said she did not know “the scope and nature of the deficiency.”

The report, called a Form 483, is issued when an FDA inspection finds deficiencies at a pharmaceutical manufacturing plant.

Johnson & Johnson confirmed that the joint venture had received the Form 483 report from the FDA after a recent inspection at its Lancaster plant. Company spokeswoman Bonnie Jacobs declined to say when the inspection occurred or exactly what it found.

In a statement, the joint venture said it “takes the issues raised by the agency seriously and is fully committed to addressing their concerns as rapidly as possible. We will provide a detailed response to the FDA and work diligently to address all observations.”

The series of recalls at the Fort Washington plant have been caused by problems including contamination with bacteria, a nauseating smell on containers, possible problems with the wrong amount of active ingredient and liquid medicines that may contain tiny metal shavings.

That factory makes nonprescription pain relievers, allergy medicine, sleeping pills and heartburn tablets. The recalled products include liquid Tylenol for infants and children, Tylenol arthritis caplets, Motrin, Benadryl, Rolaids, St. Joseph’s aspirin and Simply Sleep.

Last Thursday, Johnson & Johnson said the factory, closed in April, will remain shut down for at least another year while it replaces and upgrades manufacturing and testing equipment. About 300 of the plant’s 400 workers will lose their jobs.

Besides the eight announced recalls, Johnson & Johnson allegedly had another company quietly remove bottles of Motrin with potency problems from store shelves in 2008. J&J did not announce a recall then, and the action now is the subject of a congressional investigation.

Date: July 19, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE